NCT05918783

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Recruiting now Phase 1 Last updated 11 February 2025

What this trial tests

Phase 1 trial testing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy in Peripheral Lung Tumor in 36 participants. Currently enrolling.

Timeline

28 May 2025

Primary endpoint
30 May 2027

30 December 2028

Quick facts

Lead sponsor	Impact Biotech Ltd
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	28 May 2025
Primary completion	30 May 2027
Estimated completion	30 December 2028
Sites	1 location across United States

Drugs / interventions tested

• Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Conditions studied

• Peripheral Lung Tumor — all drugs for Peripheral Lung Tumor →

Sponsor

Impact Biotech Ltd

Who can join

18 and older, any sex, with Peripheral Lung Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects.

Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure.

Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Clinical Practice of Photodynamic Therapy for Non-Small Cell Lung Cancer in Different Scenarios: Who Is the Better Candidate?
   Sun W, Zhang Q, Wang X, Jin Z, et al · · 2024 · cited 7× · PMID 38354707 · DOI 10.1159/000535270